NASDAQ: ALZNAlzamend Neuro Inc Stock
$0.73-0.04 (-5.19%)
Updated Jun 2, 2023
ALZN Price
$0.73
Fair Value Price
N/A
Market Cap
$70.40M
52 Week Low
$0.31
52 Week High
$1.50
P/E
-4.29x
P/B
12.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$15.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.45
Operating Cash Flow
-$8M
Beta
1.03
Next Earnings
Jun 28, 2023
Ex-Dividend
N/A
Next Dividend
N/A
ALZN Overview
Alzamend Neuro, Inc., is a clinical-stage biopharmaceutical company developing products to treat neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its pipeline includes AL001 for the treatment of Alzheimer's, other neurodegenerative diseases, and psychiatric disorders, and AL002, to restore patients' immunological systems to combat Alzheimer's. The company was founded in 2016 and is headquartered in Tampa, FL.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALZN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALZN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALZN is poor value based on its book value relative to its share price (12.01x), compared to the US Biotechnology industry average (5.19x)
P/B vs Industry Valuation
ALZN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALZN due diligence checks available for Premium users.
Be the first to know about important ALZN news, forecast changes, insider trades & much more!
ALZN News
Valuation
ALZN fair value
Fair Value of ALZN stock based on Discounted Cash Flow (DCF)
Price
$0.73
Fair Value
$0.63
Overvalued by
15.65%
ALZN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALZN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.29x
Industry
11.51x
Market
52.74x
ALZN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.01x
Industry
5.19x
ALZN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALZN's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
ALZN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.5M
Liabilities
$2.6M
Debt to equity
0.45
ALZN's short-term assets ($8.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALZN's short-term assets ($8.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALZN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$0.0
Financing
$0.0
ALZN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALZN vs Biotech Stocks
Alzamend Neuro Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.